Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Alterity Therapeutics Ltd., a biotech firm focusing on neurodegenerative disease treatments, will feature in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 17th. The company’s CEO, David Stamler, M.D., will represent Alterity, which is currently advancing its lead drug candidate, ATH434, through Phase 2 clinical trials for Multiple System Atrophy. Interested parties can access the webcast live or via a three-month archive on Alterity’s website.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
